Posted by Michael Wonder on 28 Jun 2022
Health Canada approves Opdivo (nivolumab) as monotherapy for the adjuvant treatment of adults with urothelial carcinoma at high risk of recurrence after undergoing radical resection of urothelial carcinoma
28 June 2022 - First adjuvant Immunotherapy for patients at high risk of disease recurrence.
Today, Bristol Myers Squibb Canada announced Health Canada has issued a Notice of Compliance with Conditions for Opdivo, as a monotherapy for the adjuvant treatment of adult patients with urothelial carcinoma who are at high risk of recurrence after undergoing radical resection of urothelial carcinoma.
